Joined Today: 0

AMGN Amgen, Stock Message Board

All Messages

AMGN Message Board Home | Join The AMGN Group |

#103: AMGN Stock News : Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
TheMachine	May 25, 2009 11:31:08 PM
'Coping with Cancer from the Outside In' Program to Launch at the Annual Oncology Nursing Society Congress THOUSAND OAKS, Calif., April 30... view message ignore post recommend post

#102: AMGN Stock: Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
Stock News Bot	December 24, 2008 09:32:01 AM
THOUSAND OAKS, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN stock), today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug... view message ignore post recommend post

#101: Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
TheMachine	September 30, 2008 09:37:05 PM
Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s independent meta-analysis of patient-level data... view message ignore post recommend post

#100: Amgen Announces Voting Results of Annual Meeting of Stockholders
Stock News Bot	May 9, 2008 06:21:24 PM
Amgen (NASDAQ:AMGN), today announced results of voting at the company’s Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif.... view message ignore post recommend post

#99: Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting
TheMachine	April 8, 2008 02:30:13 AM
Five Investigational Compounds from Robust Ongoing Clinical Trials Program Target Novel Cancer Pathways Amgen (NASDAQ: AMGN) today announced that results from... view message ignore post recommend post

#97: Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints and Out of the Gate: Celgene Falls
FastFun	December 12, 2007 10:15:51 PM
--(www.USEquityNews.com)-- 12/11/2007 - Pharmaceutical industry alert provided by U.S. Equity News. Amgen Inc. (NASDAQ: AMGN) recently announced results from a second randomized, pivotal... view message ignore post recommend post

#96: Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
FastFun	December 10, 2007 10:05:55 PM
Data Also Shows Potential of Nplate as a Long-term Treatment Option for Chronic Adult Immune Thrombocytopenia Purpura Amgen Inc. (NASDAQ:AMGN) today announced results from a second... view message ignore post recommend post

#95: Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
FastFun	December 10, 2007 10:05:13 PM
Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Thrombocytopenic Purpura Amgen Inc. (NASDAQ:AMGN) today announced results from... view message ignore post recommend post

#94: Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs
FastFun	December 7, 2007 08:25:04 PM
Revised ESA Labeling to be Based on New Data from PREPARE and GOG Studies Amgen Inc. (NASDAQ:AMGN) today announced the company is in discussions with the U.S. Food and Drug... view message ignore post recommend post

#93: Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
FastFun	December 7, 2007 08:24:06 PM
Clinically Relevant Biomarker Provides Physicians With the Ability to Predict the Patients Most Likely to Respond to Vectibix Treatment Amgen (NASDAQ: AMGN) today announced that the... view message ignore post recommend post

#92: Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients
FastFun	December 7, 2007 08:16:56 PM
Amgen, Inc. (NASDAQ: AMGN) today announced that it had received interim results from the independent investigator-sponsored “PREPARE” study, an open-label, randomized, multicenter Phase 3... view message ignore post recommend post

#91: Amgen Hires Former Clinton Aide to Lobby and Gilead Seeks Aztreonam Lysine Approval
FastFun	November 26, 2007 08:31:13 PM
--(www.USEquityNews.com)-- 11/19/2007 - Pharmaceutical industry alert provided by U.S. Equity News. Drug maker Amgen Inc. (NASDAQ: AMGN) hired Sally Katzen, a former deputy director at... view message ignore post recommend post

#90: Gilead Sciences CEO Exercises Options and Genzyme Rises After Icahn Buys Shares
FastFun	November 26, 2007 08:28:20 PM
--(www.USEquityNews.com)-- 11/16/2007 - Pharmaceutical industry alert provided by U.S. Equity News. The president and chief executive of biopharmaceutical company Gilead Sciences Inc.... view message ignore post recommend post

#89: AMGN News Amgen to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference
Stock News Bot	March 19, 2007 09:43:00 AM
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) will participate in the Lehman Brothers Tenth Annual Global Healthcare Conference on Tuesday, March 20, 2007, at the Loews... view message ignore post recommend post

#88: AMGN News Amgen to Present at the 27th Annual Cowen & Company Health Care Conference
Stock News Bot	March 12, 2007 11:53:00 AM
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) will participate in the 27th Annual Cowen & Company Health Care Conference on Tuesday, March 13th, at the Boston... view message ignore post recommend post

Group Home | Login if you want to post a message